IAVI is a nonprofit scientific research organization focused on developing vaccines and antibodies for critical infectious diseases, including HIV, tuberculosis, and emerging viral threats like Lassa fever and Ebola. Their approach encompasses a comprehensive product development strategy that spans from grassroots initiatives to laboratory research and legislative advocacy. IAVI's mission is to translate scientific discoveries into affordable public health solutions, aiming for a world where innovative vaccines and therapeutics are equitably accessible to all. The organization is actively engaged in addressing the complexities of HIV vaccine design, pioneering next-generation vaccines and broadly neutralizing antibodies (bnAbs) to prevent HIV acquisition, while also advancing vaccine candidates for tuberculosis and other infectious diseases.

IAVI employs advanced technologies such as recombinant vesicular stomatitis virus (rVSV) vectors in the development of vaccines for Lassa fever, Marburg virus, and Sudan ebolavirus. These technologies have shown promise in clinical studies, demonstrating safety and immunogenicity. For instance, IAVI's Lassa vaccine candidate was well tolerated in Phase I trials, while preclinical data for the Marburg vaccine indicated high protection in animal models. Additionally, IAVI is working on a COVID-19 vaccine candidate based on the same rVSV technology, which has shown safety in human trials and is being produced at scale for larger studies. Through these innovative approaches, IAVI aims to address urgent global health challenges and improve access to life-saving vaccines.

United States

Translating scientific discoveries into affordable, globally accessible public health solutions. 

IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.

IAVI

Company Details